Hemispherx (HEB) Updates on FDA Panel Vote for Ampligen; Fails to Win Backing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Hemispherx Biopharma (HEB) Investors Go For Ride Following FDA Panel Vote
December 20, 2012 5:34 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) saw heavy action on Thursday after news broke that its Ampligen drug was not proven effective in treatment for chronic fatigue. An FDA panel voted 9-4 against the efficacy of the drug. Several members cited need for additional... More
Hemispherx (HEB) fails to win FDA panel backing for Ampligen efficacy
December 20, 2012 4:29 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) fails to win FDA panel backing for Ampligen efficacy.... More
